Вид документа : Статья из журнала Шифр издания : Автор(ы) : Gutorova, Nataliya, Soloviov, Oleksii, Olejnik, Dimitri Заглавие : Improper healthcare marketing: German and Ukrainian experience in prevention Место публикации : Wiadomosci lekarskie. - 2019. - Vol. 72, Issue: 12 cz 2. - P.2404-2409 УДК : 343.35:35.08 ББК : Х628.38 Ключевые слова (''Своб.индексиров.''): healthcare marketing--управление здравоохранением--управління охороною здоров'я--pharmacy crimes--аптечные преступления --аптечні злочини--corruption and medical sales representative--коррупция и медицинский торговый представитель--корупція і представництво медичних продаж Аннотация: OBJECTIVE: Introduction: Improper healthcare marketing is a part of institutional corruption in the pharmaceutical markets, which causes significant harm to public health. Legal measures are an importent component of the mechanism for preventing this phenomenon. The aim: The purpose of the article is to raise awareness and stimulate serious discussion about the necessity to improve the preventative role of law in the field of healthcare marketing by adjusting liability for offenses in this area. PATIENTS AND METHODS: Materials and methods: This study is based on the analysis of international law, medical and criminal legislation, juridical practice, criminal and medical law legal doctrine, physicians survey results and expert interviews. Dialectical, comparative, analytic, synthetic and system analyses research methods were used, also for interpretation purposes. RESULTS: Results: The study showed the effectiveness of the US fight against improper healthcare marketing by applying millions and billions of fines to the largest pharmaceutical companies in the world, which led to a reduction in corruption in this sphere. Legal restrictions on the activities of medical sales representatives of pharmaceutical companies are justified by the Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as well as in the German legislation (Medicinal Products Act). An analysis of Articles 299a and 299b of the German Criminal Code (StGB), as well as the practice of their application, showed their effectiveness. Still, there are problems in delimiting these offenses from the legal provision of drug information. The lack of anti-corruption regulation of drug promotion in Ukraine negatively affects the situation in this area. CONCLUSION: Conclusions: The legal mechanism for the prevention of improper healthcare marketing at the national level should include the following measures: a) strict legal regulation of the rules for the promotion of medicines; b) anti-corruption restrictions on the activities of medical sales representatives of pharmaceutical companies; b) the criminal liability of pharmaceutical companies for corruption in the implementation of healthcare marketing; c) the criminal liability of representatives of pharmaceutical companies and Healthcare professionals (HCPs) for active and passive briberies; d) legal support for professional self-regulation aimed at creating ethical standards of conduct in the pharmaceutical markets. Держатели документа: Web of Science Scopus Доп.точки доступа: Soloviov, Oleksii; Olejnik, Dimitri; Гуторова, Наталя Олександрівна